Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment

NCT ID: NCT02034669

Last Updated: 2014-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to assess the safety and effect of autologous adipose derived stem cell (ADSCs) transplantation in acute spinal cord injury patients.

1. To assess the safety of autologous ADSCs transplantation in acute spinal cord injury and the complication after ADSCs transplantation.
2. To evaluate the effect of ADSCs isolation and expansion procedure.
3. To determine if functional outcome is improved following ADSCs transplantation in acute spinal cord injury patient, using pre-transplantation spinal cord function as the control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The research has carried out in Phase II which is designed as randomized controlled trials.

Selection of patients began in Feb,2013, 48 patients are divided in two group according to a 2:1 ratio (the number of candidates as treated: the candidates as control).

The effectiveness of preliminary trial are evaluated by assessing Frankel/ASIA motor grade, measuring electrophysiological parameters, enhanced MRI and urinary and bowel function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Spinal Cord Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment with ADSCs transplantation

4 Intervention: laminectomy, intradural space at damage site, intrathecal at lumbar puncture, intravenous

Group Type EXPERIMENTAL

Laminectomy

Intervention Type DEVICE

surgical laminectomy with glial scar resection

Intradural space

Intervention Type DEVICE

ADSCs injection into Intradural space at damage site

Intrathecal

Intervention Type DEVICE

ADSCs Intrathecal into lumbar puncture

Intravenous

Intervention Type DEVICE

ADSCs intravenous

Treatment without ADSCs transplantation

Only intervention: laminectomy

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laminectomy

surgical laminectomy with glial scar resection

Intervention Type DEVICE

Intradural space

ADSCs injection into Intradural space at damage site

Intervention Type DEVICE

Intrathecal

ADSCs Intrathecal into lumbar puncture

Intervention Type DEVICE

Intravenous

ADSCs intravenous

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be able to give voluntary (patients may not be able to write) consent.
* Must be able to understand study information provided to him.
* Patients with complete spinal cord \< 2 weeks in acute category
* The level of spinal cord injury must be categorized at A level in terms of ASIA Impairment scale.
* Age should be between 19-60 years
* Both male and female

Exclusion Criteria

* Support respiration by machine
* Melanoma within 5 years
* Infectious diseases including HIV and Hepatitis B, C
* Brain damage or multiple trauma
* Body temperature higher 38 ℃ or acute disorder
* Anemia or thrombocytopenia
* Angina , myocardial infarction , heart disease , embolic disease , chronic renal failure, glomerular disease and chronic obstructive pulmonary disease.
* Congenital or acquired immunodeficiency disorder
* Muscular dystrophy or muscle stiffness
* Non-conscious or voice disorders
* Treatment with cytotoxic drugs ( immunosuppressive drugs , corticosteroids and cytotoxic drugs) during the clinical trials .
* Participating in another clinical trial within 3 months
* Other serious disease or disorder can seriously affect the ability to participate in research.
* Women who are pregnant or lactating .
* Allergy to antibiotics and anesthetics .
* Do not agree to participate in research
Minimum Eligible Age

19 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tri Phuoc Biotechnology., JSC

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Phuc Ba Duong, MD

Role: PRINCIPAL_INVESTIGATOR

Tri Phuoc Biotechnology., JSC

Hoa D Nguyen, MD

Role: PRINCIPAL_INVESTIGATOR

Vietnamese- German Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vietnamese- German Hospital

Hanoi, Hanoi, Vietnam

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Vietnam

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Phuc Ba Duong, MD

Role: CONTACT

+17143607716

Hoa D Nguyen, MD

Role: CONTACT

+84904613833

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Phuc Ba Duong, MD

Role: primary

+17143607716

Hoa D Nguyen, MSc, MD

Role: backup

+84904613833

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TP-VD-2012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sterile Amniotic Fluid Filtrate Epidural Injection.
NCT04537026 COMPLETED PHASE1/PHASE2
Spine Oncology Registry
NCT07225491 RECRUITING
Duraplasty for Acute Traumatic Spinal Cord Injury
NCT07280351 NOT_YET_RECRUITING NA
Prevena Spine for Use in Spine Surgery
NCT05555355 COMPLETED PHASE4